ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Suraksha Diagnostic (SURAKSHA.NSE)
Suraksha Diagnostic share price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · National Stock Exchange of India · India
₹312.65▲ +4.44%
Prices as of Oct 26, 2026 · INR
Chance of rising in 1 month
49%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Suraksha Diagnostic in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Suraksha Diagnostic
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Suraksha Diagnostic a 49% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₹289.31 and ₹336.42; in 9 out of 10, between ₹253.10 and ₹384.56. Estimated annual volatility is 46%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₹15.5B
- Market cap (USD)
- $164M
- P/E ratio
- 43.2
- Dividend yield
- 0.16%
- 52-week high
- ₹360.00
- 52-week low
- ₹224.10
- Revenue (12 months)
- ₹3.3B
- Operating margin
- 21.8%
- Net margin
- 11.0%
What this means
ATLAS does not publish a fair value for SURAKSHA.NSE right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks SURAKSHA.NSE has traded between ₹224.10 and ₹360.00. Today it is 13.2% below that high and 40% above its low.
On the business: net margin is 11.0%; it trades at 43.2 times earnings.
About the company
Suraksha Diagnostic Ltd. operates as a medical diagnostics company, providing a comprehensive range of clinical laboratory and imaging services.
Want to see everything about Suraksha Diagnostic?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Suraksha Diagnostic do?
Suraksha Diagnostic Ltd. operates as a medical diagnostics company, providing a comprehensive range of clinical laboratory and imaging services.
What is the chance SURAKSHA.NSE goes up next month?
49%: close to a coin flip. In half of the simulated outcomes, SURAKSHA.NSE ends the month between ₹289.31 and ₹336.42.
How big is Suraksha Diagnostic and what is its P/E ratio?
Suraksha Diagnostic's market capitalization is ₹15.5B. Its price-to-earnings (P/E) ratio is 43.2: you pay ₹43.2 for each ₹1.00 of yearly earnings.
Does Suraksha Diagnostic pay a dividend?
Yes. SURAKSHA.NSE's current dividend yield is 0.16% at today's price (₹312.65).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer